INTRODUCTION
============

Patients with advanced-stage head and neck squamous cell carcinoma (HNSCC) are mainly treated with the non-surgical methods of concurrent chemoradiation therapy (CCRT) or radical radiotherapy to preserve organ function and maintain the quality of life ([@B1][@B2]). Despite these rigorous treatment methods, treatment still fails at local or nodal sites in the head and neck in approximately 25--30% of patients ([@B3][@B4][@B5][@B6][@B7][@B8]). A reliable indicator for pre-treatment diagnosis of resistant HNSCC in patients could allow the CCRT regimes to be modified, or indicate the need for a switch to alternative strategies, improving their chances of success, and sparing the patients from ineffective treatment burdened by unnecessary toxicity ([@B9]). In addition, intra-treatment scanning for the adaptation of radiotherapy fields to the changing size of the tumor is already under evaluation, providing an opportunity to monitor early treatment response and adjust CCRT regimes accordingly ([@B1][@B2][@B10][@B11]). However, differentiation of residual cancer from post-treatment change using conventional magnetic resonance imaging (MRI), computed tomography (CT), 18-fluorodeoxyglucose positron emission tomography-CT (^18^F-FDG PET/CT) in the early post-treatment period is a dilemma. The morphological criteria of CT and MRI with regard to volume regression ([@B12][@B13][@B14][@B15][@B16]), change in signal intensity ([@B17][@B18]), and nodal density ([@B19][@B20]) have shown heterogeneous results in the prediction of treatment response. The image results from ^18^F-FDG PET/CT are also often suboptimal due to low spatial resolution and presence of treatment-induced inflammation during the first four months post CCRT that may be misleading ([@B21]). Endoscopy of primary sites could be hampered by radiation-induced mucositis. Biopsy of primary and nodal sites could be affected by sampling errors and may initiate superimposed infection, fail to heal, and cause worsening of complaints ([@B22]).

Diffusion-weighted imaging (DWI) is a functional MRI technique allowing the quantification of the diffusion of water molecules in a tumor by measuring the apparent diffusion coefficient (ADC). Recently, researchers have focused on DWI for predicting treatment response in patients with HNSCC, and it has been demonstrated that tumors with high ADC values are less likely to respond to chemoradiation ([@B23][@B24][@B25][@B26][@B27][@B28][@B29][@B30][@B31][@B32]). This is probably because a high ADC value may reflect the presence of micronecrosis, tumor hypoxia, high stromal content, and low cellularity (lower proliferation), which consequently increase the resistance to CCRT. In addition, the diagnostic accuracy of change in ADC values between the pre-treatment and early intra-treatment or post-treatment periods has been investigated for the prediction of treatment response, under the consideration that treatment with CCRT leads to cell death and reduction of restrictive barriers to diffusion, and therefore a consequent increase in the mean ADC value ([@B9][@B28][@B30][@B33][@B34]). However, several conflicting results have been reported ([@B9][@B25][@B34][@B35][@B36][@B37][@B38][@B39]), and previous studies have been limited by small numbers of patients and overlapping patient data ([@B22][@B29][@B30][@B31][@B32][@B34][@B40]). To the best of our knowledge, no systematic review has assessed the role of DWI in predicting locoregional failure according to pre-treatment ADC and change in ADC during early intra-treatment or post-treatment in patients with HNSCC. Therefore, we performed this systematic review to evaluate the sensitivity and specificity of pre-treatment ADC and change in ADC during the early intra-treatment or post-treatment period, for the prediction of the locoregional response to definitive CCRT or radiation therapy in patients with HNSCC.

MATERIALS AND METHODS
=====================

Literature Search Strategy
--------------------------

A computerized search of the Ovid-MEDLINE and Embase databases was performed to identify relevant original articles on the use of DWI for the prediction of locoregional treatment response in patients with HNSCC treated with definitive CCRT or radiation therapy, up until September 8, 2018. The following search terms were used: \[("head and neck") OR (oropharyngeal) OR (tongue) OR (oral cavity) OR (oropharynx) OR (hypopharyngeal) OR (hypopharynx) OR (larynx) OR (laryngeal) OR (pharynx) OR (pharyngeal)\] AND \[(carcinoma) OR (carcinomas) OR (cancer) OR (cancers)\] AND \[(chemoradiation) OR (chemoradiotherapy) OR (radiotherapy) OR (radiation therapy)\] AND \[("diffusion weighted") OR ("diffusion-weighted") OR (dw-mri) OR (DWI) OR ("apparent diffusion coefficient") OR (ADC)\]. Only studies published in English were included. The bibliographies of the selected articles were screened to identify other relevant articles.

Inclusion Criteria
------------------

Studies investigating the use of DWI for the prediction of locoregional treatment response in HNSCC were eligible for inclusion.

Studies or subsets of studies satisfying all of the following criteria were included:

1\) Population: patients with histologically proven HNSCC who underwent definitive CCRT or radiation therapy.2) Index test: imaging with MRI including DWI with provision of pre-treatment ADC value or change in the pre-treatment and early intra-treatment or post-treatment ADC values.3) Reference standard: the reference standards of the treatment outcome as determined by histologic confirmation or clinical/imaging follow-up, or a combination of these.4) Outcomes: results of locoregional failure after definitive CCRT or radiation therapy, reported in sufficient detail.5) Study design: all observational studies (retrospective or prospective).

Exclusion Criteria
------------------

The exclusion criteria were as follows: 1) case reports, review articles, editorials, letters, comments, and conference proceedings; 2) studies with insufficient data on the locoregional failure and locoregional control; 3) studies that did not provide ADC values; 4) studies that monitored the intra-treatment response during CCRT; and 5) studies with overlapping patients and data. Two reviewers independently selected appropriate study reports using a standardized form.

Data Extraction
---------------

One reviewer extracted data from the studies with the second reviewer double-checking the accuracy of the extracted data and resolving any uncertainty through discussion. The following data were extracted from each of the selected studies onto standardized data forms:

1\) Study characteristics: authors, year of publication, hospital or medical school, years of patient recruitment, sample size, and study design.2) Demographic and clinical characteristics of patients: mean age, nodule size, and patient reference standards.3) Imaging characteristics: timing of imaging, machine manufacturer and model, magnetic field strength, sequence, slice thickness, gap, and total acquisition time for DWI.4) Interpretation: number of reviewers, experience, presence of consensus data.5) True positives and negatives and false positives and negatives for the prediction of treatment response according to ADC value. In cases of incomplete 2 × 2 tables, the corresponding author was contacted, and data required to generate 2 × 2 tables was requested.

Quality Assessment
------------------

The methodological quality of the included studies was assessed independently by two reviewers using tailored questionnaires devised according to the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria ([@B41]). Disagreements were very minor and were resolved by consensus.

Data Analysis
-------------

For the diagnostic accuracy assessment, 2 × 2 data were summarized in forest plots of sensitivity and specificity for each study. Pooling was not performed because of the relatively small number of studies, relatively high risk of bias, and inherent heterogeneity based on varying study designs among the included studies. The presence of a threshold effect was visually assessed using coupled forest plots of sensitivity and specificity. The Spearman correlation coefficient between the sensitivity and false-positive rate was obtained; a value \> 0.6 was deemed a considerable threshold effect ([@B42]).

RESULTS
=======

Literature Search
-----------------

The study selection process is illustrated in [Figure 1](#F1){ref-type="fig"}. Twelve studies were included in the systematic review and seven of these presented data that could be extracted to a 2 × 2 table format to calculate sensitivity and specificity. The seven studies included four investigating the diagnostic accuracy of pre-treatment ADC ([@B25][@B26][@B28][@B30]) for predicting the locoregional treatment response, and four investigating the diagnostic accuracy of change in ADC ([@B9][@B25][@B33][@B34]).

Characteristics of the Included Studies
---------------------------------------

The characteristics of the 12 included studies are listed in [Table 1](#T1){ref-type="table"}. The 12 original articles included ten prospective studies ([@B9][@B24][@B25][@B30][@B33][@B34][@B35][@B36][@B37][@B38]), one retrospective study ([@B26]), and one study with an unclear design ([@B28]). The target lesions of the studies were primary tumors (n = 3) ([@B26][@B30][@B34]), lymph nodes (n = 4) ([@B24][@B25][@B28][@B37]), or both (n = 5) ([@B9][@B33][@B35][@B36][@B38]). Eleven studies investigated the value of pre-treatment ADC ([@B9][@B24][@B25][@B26][@B28][@B30][@B34][@B35][@B36][@B37][@B38]) for predicting locoregional treatment response, and ten studies investigated the value of change in ADC ([@B9][@B25][@B28][@B30][@B33][@B34][@B35][@B36][@B37][@B38]). All studies had a clear description of the reference standard for determining the treatment outcome, and detailed descriptions of the proportion of patients with locoregional failures and locoregional control. Among the total population of 418 patients, locoregional failure occurred in 136 patients (32.5%) and locoregional control was achieved in 282 patients (67.5%) (analysis per-patient).

All studies included pre-treatment MRI including DWI, and ten studies performed MRI at early intra-treatment or post-treatment periods, to evaluate the change in ADC value ([@B9][@B25][@B28][@B30][@B33][@B34][@B35][@B36][@B37][@B38]). The detailed technical characteristics of the MRI acquisitions are listed in [Table 2](#T2){ref-type="table"}. All of the DWI images were acquired in the axial plane using spin-echo echo-planar imaging sequences. The number of b-values used for the DWI ranged from one to ten, with majority of the studies using b-values between one and six ([@B9][@B24][@B25][@B26][@B28][@B30][@B33][@B34][@B35][@B36][@B37][@B38]). The regions of interest (ROIs) were outlined by experienced radiologists or oncologists, and were defined on either a single slice of the target lesion ([@B24][@B26][@B30][@B35][@B36][@B37]), or on every section of all targeted lesions ([@B9][@B25][@B28][@B34][@B38][@B43]).

Quality Assessment
------------------

Overall, the quality of the studies was considered moderate, with 9 of the 12 studies satisfying at least 5 of the 7 QUADAS-2 domains ([Fig. 2](#F2){ref-type="fig"}). Notable areas of quality concerns included no mention of blinding to the clinical outcomes of patients during ROI placement ([@B24][@B25][@B26][@B28][@B34][@B35][@B37][@B38]). Regarding the patient selection domain, one study was considered to have a high risk of bias due to a non-consecutive case/control study design ([@B26]). In addition, one study was considered to have an unclear risk of bias as it did not explicitly mention whether patient enrollment was prospective or not ([@B28]). Only one study had a concern for applicability, which was because majority of the included patients were tested positive for human papillomavirus (HPV) ([@B37]). With regard to the reference standard and flow and timing domain, all studies were considered to have a low risk of bias.

Pre-treatment ADC Value for Predicting Locoregional Treatment Response of HNSCC
-------------------------------------------------------------------------------

Eleven studies investigated the value of pre-treatment ADC for predicting locoregional treatment response in patients with HNSCC ([@B9][@B24][@B25][@B26][@B28][@B30][@B34][@B35][@B36][@B37][@B38]). Of these 11 studies, 5 found that pre-treatment ADC values were significantly associated with locoregional treatment response ([@B24][@B25][@B26][@B28][@B30]); in all 5 of these studies, pre-treatment ADC values were significantly higher in patients with locoregional failure than in those with locoregional control. A cut-off ADC value ranging from 0.86 to 1.2 was mentioned in 4 studies ([@B25][@B26][@B28][@B30]). In the other 6 studies that did not show a significant difference in ADC between the 2 groups, 2 studies showed lower values of pre-treatment ADC in locoregional control ([@B9][@B34]), whereas in 3 studies, the pre-treatment ADC value was higher in the locoregional control ([@B36][@B37][@B38]). In 1 study, locoregional control showed higher ADC values than locoregional failure in primary tumors, but showed lower ADC values in lymph nodes ([@B35]). The diagnostic accuracy of pre-treatment ADC values for predicting locoregional failure was assessed in 4 studies ([@B25][@B26][@B28][@B30]). [Figure 3](#F3){ref-type="fig"} is a forest plot of sensitivity and specificity for the 4 included studies. The coupled forest plots of the sensitivity and specificity for the pre-treatment ADC did not reveal any apparent threshold effect and the Spearman correlation coefficient between sensitivity and false-positive rate was −0.519 (95% confidence interval \[CI\], −0.961--0.670). Meta-analytic pooling of the sensitivity and specificity values was not performed due to the apparent heterogeneity in these values that were unexplainable with threshold effect, and infeasibility of robust analysis of the causes of heterogeneity. The total population comprised of 171 patients, with 52 patients (30.4%) having locoregional failure. The sensitivities and specificities of the 4 individual studies ranged from 50% to 100% and from 79% to 96%, respectively ([Table 3](#T3){ref-type="table"}).

Change in ADC Value for Predicting Locoregional Failure of HNSCC
----------------------------------------------------------------

Ten studies investigated the value of change in ADC for predicting locoregional treatment response in HNSCC ([@B9][@B25][@B28][@B30][@B33][@B34][@B35][@B36][@B37][@B38]). In all 10 studies, the change in ADC was larger in the patients with locoregional control than in those with locoregional failure, and 5 studies showed a statistically significant difference ([@B9][@B28][@B30][@B33][@B34]). The cut-off value for change in ADC was mentioned in 4 studies, and ranged from 15.5% to 25% ([@B9][@B25][@B33][@B34]). The time over which the change in ADC was measured ranged from one to three weeks from the start of CCRT, except for one study where the ADC was measured three weeks after completion of CCRT ([@B33]). The diagnostic accuracy of the change in ADC for predicting locoregional failure was assessed using 4 studies ([@B9][@B25][@B33][@B34]). The coupled forest plots of sensitivity and specificity for the change in ADC did not reveal any apparent threshold effect and the Spearman correlation coefficient between sensitivity and false-positive rate was −0.829 (95% CI, −0.996--0.650). ([Fig. 4](#F4){ref-type="fig"}). Meta-analytic pooling of the sensitivity and specificity values was not performed for the same reasons as those mentioned above. The total population comprised of 135 patients, with locoregional failure in 43 (31.9%). The sensitivities and specificities of the 4 individual studies ranged from 75% to 100% and from 69% to 95%, respectively ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

In the current systematic review, we demonstrated that high pre-treatment ADC and a low rise in ADC during the early intra-treatment or post-treatment periods of CCRT were indicators of locoregional failure in patients with HNSCC. Considering the consistency in the results of change in ADC obtained, we propose that it could be a promising approach to predict treatment response after CCRT.

In clinical practice, an accurate prediction of disease progression after treatment could be extremely useful for selecting the appropriate adjuvant treatment and improving the patient\'s prognosis ([@B9]). Cases of HNSCCs with high stromal content, low cellularity, and micronecrosis are associated with resistance to treatment and poor outcome ([@B44]). These tumor characteristics decrease diffusion of water molecules ([@B45][@B46][@B47]), and therefore it is hypothesized that high ADC is a predictor of poor outcome. However, the results from using pre-treatment ADC for the prediction of locoregional failure are inconsistent. The treatment response may be attributed to differences in tumor aggressiveness, HPV status, treatment protocol, or the intensity of treatment, and hence, the use of only a single ADC measurement at pre-treatment appears to be inadequate for the prediction of treatment response ([@B9][@B35]).

As response-adapted therapy becomes more widespread in cancer management, there will be greater interest in performing intra-treatment scanning ([@B44]). Increase in ADC during treatment has been correlated with the histological presence of necrosis, apoptosis, and inflammation ([@B33][@B48]), and is thought to be a useful predictor of treatment response. All of the 10 studies that investigated the role of change in ADC at early intra-treatment or post-treatment periods found consistent results ([@B9][@B25][@B28][@B30][@B33][@B34][@B35][@B36][@B37][@B38]). A lower rise in the mean ADC was found at one to three weeks after the start of treatment in patients with locoregional failure, compared to that in patients with locoregional control. This approach may be more appropriate because the change in ADC is more objective and reproducible across centers than absolute ADC values (i.e., pre-treatment ADC) ([@B44]). In many malignant tumors, it is well known that successful treatment is correlated with an increase in ADC values ([@B49][@B50][@B51][@B52][@B53]). Additionally, the ability of DWI to predict treatment outcome at one to three weeks after the start of treatment seems to be in agreement with the expected optimal timing of adjuvant neck dissection after CCRT or radiotherapy ([@B54][@B55][@B56]).

Heterogeneity was not quantified since it is an expected flaw in systematic reviews of diagnostic test accuracy. Instead, the possible sources for heterogeneity were explored. First, among the 12 studies, 3 acquired data from the primary tumors ([@B26][@B30][@B34]), 4 from lymph nodes ([@B24][@B25][@B28][@B37]), and 5 from both sites ([@B9][@B33][@B35][@B36][@B38]). The study by Wong et al. ([@B35]) found that mean pre-treatment ADC values were higher in locoregional control than in locoregional failure in primary tumors, but found opposite results in lymph nodes. It may be related to the fact that ADC values acquired from the primary sites may be more influenced by physiologic motion and susceptibility artifacts than those acquired from cervical lymph nodes ([@B9]). Second, the included studies used different numbers and distributions of b-values, with majority of the studies using one to six b-values ([@B9][@B24][@B26][@B28][@B30][@B33][@B34][@B35][@B36][@B38]), although 2 studies used nine or ten b-values ([@B25][@B37]). Recent studies show that mean ADCs obtained from high b-value ranges of 300--1000 s/mm^2^ are more appropriate for predicting treatment response than mean ADCs obtained from low b-value ranges of 0--300 s/mm^2^ ([@B27][@B30][@B44][@B57]). Finally, the HNSCC showed heterogeneous histopathology with areas of micronecrosis, even though it was not readily distinguishable on imaging. Therefore, the use of the mean ADC of the whole tumor is considered more accurate than the measurement from a single section ROI ([@B9]).

The prediction of tumor response with ADC offers several advantages over the use of other imaging modalities like ^18^F-FDG PET/CT, contrast-enhanced MRI, magnetic resonance spectroscopy, and dynamic contrast-enhanced MRI. These include: absence of the need for injection of an isotope or contrast agent, short acquisition time, and simple estimation. Despite these advantages of ADC, the clinical use of ADC for the prediction of tumor response in HNSCC presents challenges due to susceptibility and motion artifacts. Furthermore, there is no clear threshold for the differentiation between locoregional failure and locoregional control. Finally, different MRI systems and different b-values have been used in previous studies. This means that the use of ADC cannot be extrapolated across hospital sites. Thus, further clinical studies to standardize and validate ADC measurements are necessary.

This study was limited by the relatively few included studies and its potential heterogeneity. This precluded our ability to perform meta-analysis, analyze subgroups, and identify potentially important covariates. When sufficient papers have been published in the future, a meta-analysis considering the factors that may cause heterogeneity may be performed.

In conclusion, high pre-treatment ADC and a low rise in ADC during the early intra-treatment or post-treatment periods of CCRT could be indicators of locoregional failure in patients with HNSCC. Considering the consistency of the results obtained with change in ADC, we propose that it could be used to identify patients who require more aggressive investigations to identify any residual cancer. However, as the studies are few, heterogeneous, and at high risk for bias, the sensitivity and specificity of these parameters for predicting treatment response are yet to be determined. Continued research on standardization and validation of ADC measurement, and determination of the optimal threshold for percentage change, are required for clinical use.
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###### Characteristics of Included Studies
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  First Author (Publication Year) (Ref.)   Affiliated Institute                                                                                      Study Period   No. of Patients   Mean Age, Year (Range)   Primary Tumor Location                                                                              Stage                                                       Treatment                             Outcome                                           Target Lesion                  Timing of MRI                                                                                                                                                 Follow-Up Period
  ---------------------------------------- --------------------------------------------------------------------------------------------------------- -------------- ----------------- ------------------------ --------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------- ------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  Galbán (2009) ([@B38])                   University of Michigan Medical School, Ann Arbor, MI, USA                                                 N/A            15                N/A                      Oropharynx (12), nasopharynx (1), hypopharynx (1), unknown (1)                                      T1/2 (9), T3/4 (5), Tx (1), N0/1 (1), N2/3 (14)             CCRT                                  CR/PR                                             Primary tumor and lymph node   1 week before treatment, 3 weeks after initiation of treatment                                                                                                6 months after initiation of treatment
  Hatakenaka (2011) ([@B30])               Kyushu University Hospital, Fukuoka, Japan                                                                2006--2008     17                64 (37--85)              Oropharynx (7), hypopharynx (8), larynx (1), oral cavity (1)                                        T1/2 (7), T3/4 (10), N0/1 (5), N2/3 (12)                    CCRT (13), RT (4)                     Local control/failure                             Primary tumor                  8 days before treatment, 1 week after initiation of treatment                                                                                                 Local failure (4.6 months), local control (23.6 months)
                                                                                                                                                     2006--2009     40                64 (37--85)              Oropharynx (15), hypopharynx (19), larynx (4), oral cavity (2)                                      T1/2 (21), T3/4 (19), N0/1 (14), N2/3 (26)                  CCRT (35), RT (5)                     Local control/failure                             Primary tumor                                                                                                                                                                                Local failure (4.9 months), local control (16.4 months)
  Kim (2009) ([@B28])                      University of Pennsylvania, Philadelphia, PA, USA                                                         2005--2007     33                61 (N/A)                 Oropharynx (21), larynx (7), unknown (5)                                                            T0 (1), T1/2 (10), T3/4 (15), Tx (7), N0/1 (2), N2/3 (31)   CCRT (26), RT + immunotherapy (7)     CR/PR                                             Lymph node                     Before treatment, 1 week after initiation of treatment, 2 weeks after completion of treatment                                                                 2 weeks after termination of treatment
  King (2013) ([@B34])                     Hong Kong Cancer Institute and Prince of Wales Hospital, Shatin, Hong Kong SAR, China                     2004--2008     37                57 (45--71)              Oral cavity or oropharynx (14), nasal cavity (2), hypopharynx or larynx (20), maxillary sinus (1)   T1/2 (9), T3/4 (28)                                         CCRT (33), RT (4)                     Local control/failure                             Primary tumor                  Before treatment, 2 weeks after initiation of treatment, 6, 12, 18, 24 months after completion of treatment                                                   Local failure (3.8 months), local control (43.9 months)
  Lombardi (2017) ([@B26])                 Maggiore della Carita University Hospital, University of Eastern Piedmont, Corso Mazzini, Novara, Italy   2010--2014     47                59 (N/A)                 Nasopharynx (23), oropharynx (19), hypopharynx (5)                                                  T1/2 (14), T3/4 (33), N0/1 (21), N2/3 (26)                  CCRT (39), neoadjuvant CTx + RT (8)   Local control/disease recurrence or persistence   Primary tumor                  Before treatment                                                                                                                                              Disease recurrence or persistence (3--20 months), local control (10--36 months)
  Marzi (2017) ([@B25])                    Regina Elena National Cancer Institute, Via Elio Chianesi, Rome, Italy                                    2010--2013     34                54.5 (28--79)            Oropharynx (14), nasopharynx (13), hypopharynx or larynx (6), unknown (1)                           T0/1/2 (21), T3/4 (13), N1/2 (29), N3 (5)                   CCRT                                  Regional control/failure                          Lymph node                     Before treatment, 16--17 days after initiation of treatment, immediately and 8 weeks after completion of treatment, per 6 months for 2 years, then annually   Regional failure (6.8 months), regional control (27.6 months)
  Matoba (2014) ([@B9])                    Kanazawa Medical University, Ishikawa, Japan                                                              2008--2012     35                66.5 (33--79)            Oropharynx (9), larynx (10), supraglottis (3), hypopharynx (9), oral cavity (4)                     T1/2 (15), T3/4 (20), N0/1 (10), N2/3 (25)                  CCRT                                  Locoregional control/failure                      Primary tumor and lymph node   Before treatment, 3 weeks after initiation of treatment, then per 6 months                                                                                    30.8 months
  Ng (2014) ([@B24])                       Chang Gung Memorial Hospital, Chang Gung University, Kueishan, Taoyuan, Taiwan                            2010--2012     69                50 (39--78)              Oropharynx (37), hypopharynx (32)                                                                   III (3), IVA (50), IVB (16)                                 CCRT                                  Neck control/failure                              Lymph node                     Before, 3 months after completion of treatment, then per 6 months                                                                                             31 months
  Ng (2014) ([@B24])                       Chang Gung Memorial Hospital, Chang Gung University, Kueishan, Taoyuan, Taiwan                            2010--2012     69                50 (39--78)              Oropharynx (37), hypopharynx (32)                                                                   III (3), IVA (50), IVB (16)                                 CCRT                                  Neck control/failure                              Lymph node                     Before, 3 months after completion of treatment, then per 6 months                                                                                             31 months
  Paudyal (2017) ([@B37])                  Memorial Sloan Kettering Cancer Center, New York, NY, USA                                                 2013--2015     34                N/A (32--82)             Oropharynx (32), unknown (2)                                                                        III (2), IVA (32)                                           CCRT (33), RT (1)                     CR/non-CR                                         Lymph node                     Before treatment, 1, 2, and 3 weeks after initiation of treatment                                                                                             3--6 months after termination of treatment
  Schouten (2014) ([@B36])                 VU University Medical Center, Amsterdam, Netherlands                                                      N/A            8                 60.9 (51--68)            Oropharynx (7), hypopharynx (1)                                                                     T2 (3), T3/4 (5), N1 (1), N2/3 (7)                          CCRT                                  Regional control/ failure                         Primary tumor and lymph node   Before treatment, 14 days after initiation of treatment, per 3 months after completion of treatment                                                           38 months
  Wong (2016) ([@B35])                     Royal Marsden NHS Foundation Trust, Sutton and London, UK                                                 2013--2015     20                63 (47--69)              Oropharynx (18), hypopharynx/ larynx (2)                                                            T1/2 (11), T3/4 (9), N0/1 (2), N2/3 (18)                    Induction CTx + CCRT                  Responder/ nonresponder                           Primary tumor and lymph node   2 weeks after initiation of treatment                                                                                                                         3 months after termination of treatment

CCRT = concurrent chemoradiation therapy, CR = complete response, CTx = chemotherapy, MRI = magnetic resonance imaging, N/A = not available, PR = partial response, RT = radiation therapy

###### Technical Characteristics of Included Studies
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  First Author (Year of Publication) (Ref.)   Vendor          Model                    Field Strength (T)   DWI Sequence   Number of b-Values (Strength)                        DWI Parameters                                                                                                                                    ROI Definition (Number Persons, Experience in Years)              ROI Extent       Blindness to Reference Standard
  ------------------------------------------- --------------- ------------------------ -------------------- -------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------- ---------------------------------
  Galbán (2009) ([@B38])                      Philips         Achieva                  3                    SSEPI          2 (0, 800)                                           TR/TE = 5000/77--100, NEX: 2, FOV: 240 x 192 mm, slice thickness: 6 mm, time: 5 min, matrix: 120 x 97                                             Radiologist or oncologist (2, N/A)                                Volume           N/A
  Hatakenaka (2011) ([@B30])                  Philips         Intera                   Achieva 1.5          SSEPI          7 (0, 100, 200, 300, 500, 750, 1000)                 TR/TE = 3000/73, NEX: 2, bandwidth: 1645.9, time: 4 min 6 sec, matrix: 256 x 112                                                                  Radiologists (2, \> 15 yr)                                        Single section   Yes
  Kim (2009) ([@B28])                         Siemens         Sonata, Trio             1.5 or 3             SSEPI          3 (0, 500, 1000)                                     TR/TE = 4000/89, signal average: 4                                                                                                                Radiologist (1, N/A)                                              Volume           N/A
  King (2013) ([@B34])                        Philips         Intera NT                1.5                  SSEPI          6 (0, 100, 200, 300, 400, 500)                       TR/TE = 2000/75, slice thickness: 4 mm, gap: 0, FOV: 230 mm, acquisition matrix: 112 x 112, reconstruction matrix: 256 x 256, signal average: 4   Radiologist (1, \> 15 yr)                                         Volume           N/A
  Lombardi (2017) ([@B26])                    Philips         Achieva                  1.5                  EPI            3 (0, 500, 1000)                                     N/A                                                                                                                                               Radiologist (1, 5 yr)                                             Single section   N/A
  Marzi (2017) ([@B25])                       GE Healthcare   Optima                   1.5                  SSEPI          9 (0, 25, 50, 75, 100, 150, 300, 500, 800)           TR/TE = 4500/77, slice thickness: 4 mm, gap: 5 mm, bandwidth: 1953, FOV: 260--280 mm, acquisition matrix: 128 x 128, time: 6 min 13 sec           Radiologists (2, 15, and 6 yr)                                    Volume           N/A
  Matoba (2014) ([@B9])                       Siemens         Avanto                   1.5                  SSEPI          3 (0, 90, 800)                                       TR/TE = 4000/68, TI: 180, matrix: 512 x 256, FOV: 25, section thickness: 6 mm, gap: 3 mm                                                          Radiologists (2, 15, and 20 yr)                                   Volume           Yes
  Ng (2014) ([@B24])                          Siemens         Magnetom Trio with TIM   3                    SSEPI          2 (0, 800)                                           TR/TE = 8200/84, time: 2 min 28 sec, slice thickness: 5 mm                                                                                        Radiologist (1, \> 20 yr)                                         Single section   N/A
  Paudyal (2017) ([@B37])                     Philips         Ingenia                  3                    SSEPI          10 (0, 20, 50, 80, 200, 300, 500, 800, 1500, 2000)   TR/TE = 4000/minimum, NA: 2, matrix: 128 x 128, FOV: 20--24, slices: 8--10, slice thickness: 5 mm, time: 5 min                                    Radiation oncologist (1, \> 5 yr) and radiologist (1, \> 10 yr)   Single section   N/A
  Schouten (2014) ([@B36])                    Siemens         Sonata                   1.5                  EPI, HASTE     3 (0, 500, 1000)                                     TR/TE = 5000/105, in-plane pixel size: 2 x 2 mm                                                                                                   Radiologist (1, 29 yr)                                            Single section   Yes
  Vandecaveye (2012) ([@B33])                 Siemens         SONATA                   Vision               1.5            SSEPI 6 (0, 50, 100, 500, 750, 1000)                 TR/TE = 7100/84, matrix: 104 x 128, 44 slices, slice thickness: 4 mm, gap: 0.4 mm, FOV: 20 x 25                                                   Radiologist (1, 6 yr)                                             Volume           Yes
  Wong (2016) ([@B35])                        Siemens         MAGNETOM Aera            1.5                  SSEPI          3 (50, 400, 800)                                     TR/TE = 13400/61, matrix: 96, FOV: 199 x 199, bandwidth: 1000                                                                                     Radiation oncologist (1, N/A) and radiologist (1, N/A)            Single section   N/A

DWI = diffusion-weighted imaging, EPI = echo-planar imaging, FOV = field of view, HASTE = HAlf fourier Single-shot Turbo spin-Echo, NA = number of averages, NEX = number of excitations, ROI = region of interest, SSEPI = single-shot spin-echo EPI, T = tesla, TE = echo time, TI = inversion time, TR = repetition time

###### Summary of Diagnostic Accuracy of Pre-Treatment ADC Value in Predicting Locoregional Failure in HNSCC

![](kjr-20-649-i003)

  Study                                                  Total   TP   FP   FN   TN   Sensitivity   Specificity
  ------------------------------------------------------ ------- ---- ---- ---- ---- ------------- -------------
  Hatakenaka et al., 2011 ([@B30]) (prospective group)   17      8    1    0    8    1.00          0.89
  Hatakenaka et al., 2011 ([@B30]) (validation set)      40      12   1    1    26   0.92          0.96
  Kim et al., 2009 ([@B28])                              33      5    4    2    22   0.71          0.85
  Marzi et al., 2017 ([@B25])                            34      7    5    3    19   0.70          0.79
  Lombardi et al., 2017 ([@B26])                         47      7    5    7    28   0.50          0.85

ADC = apparent diffusion coefficient, FN = false negative, FP = false positive, HNSCC = head and neck squamous cell carcinoma, TN = true negative, TP = true positive

###### Summary of Diagnostic Accuracy of Change in ADC Value in Predicting Locoregional Failure in HNSCC

![](kjr-20-649-i004)

  Study                               Total   TP   FP   FN   TN   Sensitivity   Specificity
  ----------------------------------- ------- ---- ---- ---- ---- ------------- -------------
  Vandecaveye et al., 2012 ([@B33])   30      8    1    0    21   1.00          0.95
  Matoba et al., 2014 ([@B9])         35      14   4    0    17   1.00          0.81
  Marzi et al., 2017 ([@B25])         28      6    6    2    14   0.75          0.70
  King et al., 2013 ([@B34])          30      10   5    3    12   0.77          0.71
